secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K/A
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001213900-25-119893
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds corrects Merger Agreement errors: Preferred Stock issuance rises to 90.9% of equity
--------------------------------------------------------------------------------

- Corrected Merger Agreement removes Sections 2.05(b)/(d) (director appointment).
- Common Stock Cap corrected from 29.9% to 0% of Acquiror Common Stock outstanding.
- Preferred Stock issuable to Company stockholders corrected from 61% to 90.9% of fully diluted equity.
- Corrected Certificate of Designation increases Series A Preferred designated shares from 7,263,865 to 7,477,017.
- Amendment to Securities Purchase Agreement extends Initial Closing date and expands investor notification rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025119893/0001213900-25-119893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390025119893/ea0268649-8ka1_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-119893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer